RPL39L

Across TCGA pan-cancer cohorts, RPL39L Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RPL39L data layer compared with 28 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher RPL39L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPL39L expression acts as an unfavorable survival marker.

SARC, ESCA, and HNSC are the cancer types where RPL39L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.016	0.861	<.001	12	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
HNSC	DFS	Median	All	0.132	0.625	.037	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RPL39L–SARC (OS)

Open the SARC breakdown →